‌

US Patent 11634407 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Patent 11634407 was granted and assigned to Celgene on April, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Celgene

Current Assignee

Celgene

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

116344070

Patent Inventor Names

Stephen Norris0

Veronique Plantevin-Krenitsky0

Virginia Heather Sharron Grant0

Dehua Huang0

Brandon W. Whitefield0

Christopher Mayne0

Deepak Dalvie0

Evan J. Horn0

...

Date of Patent

April 25, 2023

Patent Application Number

173563700

Date Filed

June 23, 2021

Patent Citations

‌

US Patent 11325889 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

‌

US Patent 11149007 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Patent Citations Received

‌

US Patent 12103920 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

‌

US Patent 11883393 Compounds and methods for the targeted degradation of androgen receptor

Patent Primary Examiner

‌

Brian J Davis

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11634407 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API